2025. Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), s553. DOI:https://doi.org/10.25251/skin.10.supp.553.